HippoFi Continues to Deliver Sales Growth Adding 14 Major Healthcare Facilities

Expanding our reach in 2024, HippoFi and PUR Biologics are setting new standards in innovative spine care solutions.

IRVINE, CA / ACCESSWIRE / December 5, 2023 / (OTC PINK:ORHB) HippoFi's wholly owned subsidiary, PUR Biologics, is advancing its distribution network with a significant expansion in California. This not only broadens access to major medical facilities, but also underscores the Company's commitment to providing healthcare professionals and patients with the highest level of service and quality.

PUR Biologics is known for its comprehensive suite of best-in-class spinal biologics. With a focus on regenerating bone, cartilage, and spinal discs, PUR Biologics is positioned as a leader in the field of spinal biologics.

With a growing nationwide network of skilled representatives, PUR Biologics has the capability to service every hospital and ambulatory surgery center in the U.S.A., ensuring expert coverage across the country.

"As PUR Biologics expands, we're not just growing our footprint; we are continuously reinforcing our leadership in business and scientific innovation. Our progress in spinal biologics reflects our commitment to advancing healthcare technologies and solutions." - Ryan Fernan, Head of PUR Biologics

In the U.S., the market for instrumented spine surgeries, involving 1.62 million surgeries annually, is estimated to be worth $3.5 billion and is experiencing a steady growth with a CAGR of 4.5%.

"Our business design continues to prove our rapid ability to gain hospital approvals, deliver innovation, and continually expand our worldwide sales network for the benefit of improving patient lives." -CJ Wiggins, HippoFi Executive Chairman and CEO

----

About PUR Biologics

PUR Biologics, a wholly owned subsidiary of HippoFi, Inc. (OTCPK: ORHB), is a leading biologic company committed to supporting surgeons and hospitals in providing the best care for their patients. PUR Biologics' full line of biologic products currently include: advanced allografts and demineralized extracellular matrixes (d-ECM), innovative synthetic solutions, cellular derived tissues, and a future of next generation regenerative stem cell and growth factor driven therapeutics for treating osteoarthritis and cartilage regeneration.

About HippoFi, Inc.

HippoFi is a healthcare innovator and publicly traded company, delivering proprietary technologies in the multi-billion-dollar Spine, Orthopedic, and Cancer markets. The company's purpose is to improve patient care and outcomes by utilizing biotech and AI technologies to address degenerative and diseased conditions affecting the quality of life.

HippoFi's business is designed to drive company value by commercializing and monetizing innovative solutions, acquiring assets, and licensing technologies, establishing strategic partnerships and industry alliances, and leveraging its worldwide sales channels. The operations of the company comprise of two segments: Regenerative Therapeutics and Intelligent Automation.

HippoFi's Regenerative Therapeutics division is actively developing and deploying scalable biological solutions into the $1.37 Trillion (13.96% CAGR) biotechnology market through its wholly-owned subsidiary - PUR Biologics.

Capitalizing on HippoFi's established partnerships with ZIMMER / BIOMET, Hoag Hospital Newport Beach, BPB Medica, Precision Spine, and others, PUR Biologics' team of industry experts, pioneering scientists, and world-class medical professionals are utilizing the company's powerful patent portfolio and proprietary technologies to commercialize advanced technologies that improve bone growth in spinal fusion procedures, regenerate joint cartilage and intervertebral disc, eliminate pain and inflammation associated with osteoarthritis, joints, and the lower back, and deliver a cell-based immunotherapy to help defeat cancer.

HippoFi, Inc. is publicly traded under the symbol: ORHB and is headquartered in Irvine, California. For more information, please visit: www.HippoFi.com and www.PURbiologics.com.

Contact

HippoFi, Inc.
949-323-2330
info@hippofi.com

SOURCE: HippoFi, Inc.